About Bristol-Myers Squibb Company
https://www.bms.comBristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.
CEO
Christopher S. Boerner
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2001-08-07 | Forward | 1000000:951777 |
| 1999-03-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 812
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
B of A Securities
Buy
Guggenheim
Buy
Jefferies
Buy
Wells Fargo
Equal Weight
Scotiabank
Sector Perform
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:195.98M
Value:$11.18B
BLACKROCK, INC.
Shares:175.52M
Value:$10.01B
BLACKROCK INC.
Shares:158.66M
Value:$9.05B
Summary
Showing Top 3 of 3,213
About Bristol-Myers Squibb Company
https://www.bms.comBristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $12.22B ▼ | $5.15B ▲ | $2.2B ▲ | 18.01% ▲ | $1.08 ▲ | $4.59B ▲ |
| Q2-2025 | $12.27B ▲ | $3.95B ▲ | $1.31B ▼ | 10.68% ▼ | $0.64 ▼ | $3.29B ▼ |
| Q1-2025 | $11.2B ▼ | $3.82B ▼ | $2.46B ▲ | 21.93% ▲ | $1.21 ▲ | $4.48B ▲ |
| Q4-2024 | $12.34B ▲ | $4.89B ▲ | $72M ▼ | 0.58% ▼ | $0.04 ▼ | $2.55B ▼ |
| Q3-2024 | $11.89B | $4.33B | $1.21B | 10.18% | $0.6 | $4.77B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $16.5B ▲ | $96.89B ▲ | $78.29B ▲ | $18.55B ▲ |
| Q2-2025 | $13.6B ▲ | $94.68B ▲ | $77.19B ▲ | $17.43B ▲ |
| Q1-2025 | $11.78B ▲ | $92.43B ▼ | $74.98B ▼ | $17.39B ▲ |
| Q4-2024 | $10.86B ▲ | $92.6B ▼ | $76.22B ▼ | $16.34B ▼ |
| Q3-2024 | $8.09B | $93.67B | $76.47B | $17.14B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.19B ▲ | $6.31B ▲ | $-1.7B ▼ | $-1.49B ▲ | $3.12B ▲ | $5.99B ▲ |
| Q2-2025 | $1.31B ▼ | $3.92B ▲ | $-473M ▲ | $-1.84B ▼ | $1.74B ▲ | $3.56B ▲ |
| Q1-2025 | $2.46B ▲ | $1.95B ▼ | $-499M ▼ | $-993M ▲ | $528M ▼ | $1.69B ▼ |
| Q4-2024 | $76M ▼ | $4.44B ▼ | $-196M ▲ | $-1.64B ▲ | $2.45B ▲ | $4.06B ▼ |
| Q3-2024 | $1.22B | $5.59B | $-219M | $-3.85B | $1.6B | $5.27B |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 Abecma | $100.00M ▲ | $100.00M ▲ | $140.00M ▲ | $90.00M ▼ |
 Abraxane | $170.00M ▲ | $100.00M ▼ | $70.00M ▼ | $100.00M ▲ |
 Breyanzi | $260.00M ▲ | $260.00M ▲ | $360.00M ▲ | $340.00M ▼ |
 Camzyos | $220.00M ▲ | $160.00M ▼ | $300.00M ▲ | $260.00M ▼ |
 Cobenfy | $0 ▲ | $30.00M ▲ | $40.00M ▲ | $40.00M ▲ |
 Eliquis | $3.19Bn ▲ | $3.56Bn ▲ | $3.75Bn ▲ | $3.68Bn ▼ |
 Krazati | $40.00M ▲ | $50.00M ▲ | $50.00M ▲ | $50.00M ▲ |
 Opdivo | $2.48Bn ▲ | $2.27Bn ▼ | $2.53Bn ▲ | $2.56Bn ▲ |
 Opdivo Ovantig | $0 ▲ | $10.00M ▲ | $70.00M ▲ | $30.00M ▼ |
 Opdualag | $250.00M ▲ | $250.00M ▲ | $300.00M ▲ | $280.00M ▼ |
 Orencia | $1.00Bn ▲ | $770.00M ▼ | $960.00M ▲ | $960.00M ▲ |
 Other Growth Brands | $510.00M ▲ | $400.00M ▼ | $510.00M ▲ | $470.00M ▼ |
 Other Legacy Brands | $250.00M ▲ | $200.00M ▼ | $180.00M ▼ | $220.00M ▲ |
 PomalystImnovid | $820.00M ▲ | $660.00M ▼ | $680.00M ▲ | $710.00M ▲ |
 Reblozyl | $550.00M ▲ | $480.00M ▼ | $610.00M ▲ | $570.00M ▼ |
 Revlimid | $1.34Bn ▲ | $940.00M ▼ | $570.00M ▼ | $840.00M ▲ |
 Sotyktu | $80.00M ▲ | $60.00M ▼ | $80.00M ▲ | $70.00M ▼ |
 Sprycel | $200.00M ▲ | $170.00M ▼ | $120.00M ▼ | $120.00M ▲ |
 Yervoy | $680.00M ▲ | $620.00M ▼ | $740.00M ▲ | $730.00M ▼ |
 Zeposia | $160.00M ▲ | $110.00M ▼ | $160.00M ▲ | $150.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 Other Region | $350.00M ▲ | $270.00M ▼ | $290.00M ▲ | $220.00M ▼ |
 Rest of World | $3.40Bn ▲ | $3.48Bn ▲ | $0 ▼ | $3.11Bn ▲ |
 UNITED STATES | $8.60Bn ▲ | $8.52Bn ▼ | $8.33Bn ▼ | $7.87Bn ▼ |
CEO
Christopher S. Boerner
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2001-08-07 | Forward | 1000000:951777 |
| 1999-03-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 812
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
B of A Securities
Buy
Guggenheim
Buy
Jefferies
Buy
Wells Fargo
Equal Weight
Scotiabank
Sector Perform
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:195.98M
Value:$11.18B
BLACKROCK, INC.
Shares:175.52M
Value:$10.01B
BLACKROCK INC.
Shares:158.66M
Value:$9.05B
Summary
Showing Top 3 of 3,213